SHOWNOTES

In this episode, the Telltales team discusses the implications of Elon Musk's massive AI training cluster on the semiconductor industry, the future of self-driving cars, and the shifting landscape of chip manufacturing. They also explore the potential impact of Trump's FDA pick on healthcare costs and the U.S. budget.

[00:06:27] Limits to GPU Scaling (Page 1) Jason and Mike discuss the limitations of scaling GPU clusters for AI training, with Elon Musk's plans to expand Tesla's cluster from 100,000 to 1 million GPUs. They explore the challenges of power consumption, data center capacity, and the potential solutions, such as linking data centers together.

[00:11:21] TSMC Arizona Yield Comparison (Page 3) The team examines the success of TSMC's Arizona fab, which is producing 3nm chips with better yields than its Taiwan counterpart. They discuss the implications for U.S. participation in the semiconductor industry and the potential for TSMC to become a monopoly in leading-edge chip production.

[00:17:00] Potential Suitors for Intel (Page 3) With Jeff Bezos back at Amazon, the team speculates on whether he or Elon Musk could be suitable candidates to turn around Intel's struggling foundry business. They discuss the challenges and opportunities of such an acquisition and its potential impact on the semiconductor industry.

[00:19:00] Neural Networks for Full Self Driving Jason explains how Tesla's approach to autonomous driving differs from other companies, using neural networks trained on vast amounts of video data rather than detailed street maps. The team discusses the implications of this approach, including the potential for licensing the technology to other automakers.

[00:25:25] Vertex's Manufacturing Partnership and Sickle Cell Treatment (Page 15) Jason shares news about Vertex's partnership with Saudi Arabia to develop a gene therapy production facility, targeting the country's high prevalence of sickle cell disease. The team also touches on the lack of updates regarding Vertex's pain medicine and diabetes treatment.

[00:27:27] Trump's FDA Pick and Healthcare Price Transparency (Page 20 and Exhibit A) The team discusses the nomination of Marty McCary, a Harrow board member, to head the FDA. They explore his ideas for reducing healthcare costs through price transparency and the potential impact on the U.S. budget, given that healthcare accounts for a significant portion of government spending.

The Telltales team covers a wide range of topics, from the cutting-edge developments in AI and self-driving cars to the shifting landscape of semiconductor manufacturing and the potential for healthcare reform under the new administration. Stay tuned for more insights and analysis on the industries shaping our future.

This podcast and the information herein are intended for informational purposes only. The views expressed herein are the author’s alone and do not constitute an offer to sell, or a recommendation to purchase, or a solicitation of an offer to buy, any security, nor a recommendation for any investment product or service. While certain information contained herein has been obtained from sources believed to be reliable, neither the author nor any of his employers or their affiliates have independently verified this information, and its accuracy and completeness cannot be guaranteed. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, timeliness or completeness of this information. The author and all employers and their affiliated persons assume no liability for this information and no obligation to update the information or analysis contained herein in the future.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit telltales.substack.com